Literature DB >> 17332339

K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.

Paul M Campbell1, Angela L Groehler, Kwang M Lee, Michel M Ouellette, Vladimir Khazak, Channing J Der.   

Abstract

Mutational activation of the K-Ras oncogene is well established as a key genetic step in the development and growth of pancreatic adenocarcinomas. However, the mechanism by which aberrant Ras signaling promotes uncontrolled pancreatic tumor cell growth remains to be fully elucidated. The recent use of primary human cells to study Ras-mediated oncogenesis provides important model cell systems to dissect this mechanism. We have used a model of telomerase-immortalized human pancreatic duct-derived cells (E6/E7/st) to study mechanisms of Ras growth transformation. First, we found that human papillomavirus E6 and E7 oncogenes, which block the function of the p53 and Rb tumor suppressors, respectively, and SV40 small t antigen were required to allow mutant K-Ras(12D) growth transformation. Second, K-Ras(12D) caused growth transformation in vitro, including enhanced growth rate and loss of density dependency for growth, anchorage independence, and invasion through reconstituted basement membrane proteins, and tumorigenic transformation in vivo. Third, we determined that the Raf, phosphatidylinositol 3-kinase (PI3K), and Ral guanine nucleotide exchange factor effector pathways were activated, although extracellular signal-regulated kinase (ERK) activity was not up-regulated persistently. Finally, pharmacologic inhibition of Raf/mitogen-activated protein kinase/ERK and PI3K signaling impaired K-Ras-induced anchorage-independent growth and invasion. In summary, our studies established, characterized, and validated E6/E7/st cells for the study of Ras-induced oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332339     DOI: 10.1158/0008-5472.CAN-06-3752

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  111 in total

1.  Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1.

Authors:  Gregory P Botta; Mauricio J Reginato; Maximilian Reichert; Anil K Rustgi; Peter I Lelkes
Journal:  Mol Cancer Res       Date:  2011-12-08       Impact factor: 5.852

Review 2.  Emerging role of the KRAS-PDK1 axis in pancreatic cancer.

Authors:  Riccardo Ferro; Marco Falasca
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

4.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

5.  Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Authors:  Dapeng Xu; Michael G Cobb; Lily Gavilano; Sam M Witherspoon; Daniel Williams; Catherine D White; Pietro Taverna; Brian K Bednarski; Hong Jin Kim; Albert S Baldwin; Antonio T Baines
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

6.  Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells.

Authors:  Shujie Zhao; Yubao Wang; Lin Cao; Michel M Ouellette; James W Freeman
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

7.  PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis.

Authors:  Sohee Jun; Sunhye Lee; Han-Cheon Kim; Christopher Ng; Andrea M Schneider; Hong Ji; Haoqiang Ying; Huamin Wang; Ronald A DePinho; Jae-Il Park
Journal:  Cell Rep       Date:  2013-10-31       Impact factor: 9.423

Review 8.  Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Authors:  Catherine M Sielaff; Shaker A Mousa
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

9.  Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.

Authors:  Shao-Jie Chen; Yin-Ting Chen; Lin-Juan Zeng; Qiu-Bo Zhang; Guo-da Lian; Jia-Jia Li; Ke-Ge Yang; Chu-Mei Huang; Ya-Qing Li; Zhong-Hua Chu; Kai-Hong Huang
Journal:  Tumour Biol       Date:  2016-03-08

10.  Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling.

Authors:  Jean-Paul De La O; L Charles Murtaugh
Journal:  Cell Cycle       Date:  2009-06-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.